Biotech financing update: December 2018 to February 2019

Chris Molloy discusses Government engagement, the King’s Speech, health data, Isomorphic’s huge raise, the Start-up Festival and expanding BIA’s reach

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

Four of the most significant opportunities currently available to engage with global industry leaders

BIA CEO Chris Molloy discusses the vision for data report, rare disease R&D, Women in Biotech, Europe GMO rules, Bio€quity and Swiss Biotech Day

The project will focus on advancing MDX-201, an innovative ADC that links a cytotoxic payload with a first-in-class monoclonal antibody (MDX-124) that targets annexin-A1.